

International multi-centre clinical trials in kidney disease: ACTIVE trial & RESOLVE trial

01:00-02:00 PM, 20 Oct. 2015

Language: English

The George Institute for Global Health at Peking University Health Science Center
Room B 1801, Horizon Tower, No.6 Zhichun Rd, Haidian District, Beijing
北京大学医学部乔治健康研究所培训室, 北京海淀区知春路 6 号锦秋国际大厦 B1801 室

Prof. Meg Jardine
Deputy Director
Renal & Metabolic Division
The George Institute for Global Health
University of Sydney



About the speaker

A/Professor Meg Jardine is a clinical researcher investigating the epidemiology and complications of kidney disease and diabetes. She is currently supported by a co-funded Australian National Health and Medical Research Council Career Development Fellowship and National Heart Foundation Future Leader Fellowship. She is Head of George Clinical Renal Trials, Deputy Director of the Renal Division of The George Institute, a Conjoint A/Professor of Medicine at The University of Sydney, the Deputy Chair of the Australasian Kidney Trials Network (AKTN) and a practising nephrologist at Concord Repatriation General Hospital, a University of Sydney teaching hospital. She leads the conduct of hemodialysis trials and has key roles in the development and implementation of multiple international multi-centre clinical trials in kidney disease.

About the lecture

Despite the availability of life-preserving haemodialysis, people with end stage kidney disease do not have the same life expectancy as people with normal kidney disease. Quality of life is impaired with patients typically experiencing an increased burden of symptoms including fatigue, lethargy, loss of appetite and itch. This talk will review trials designed to improve meaningful clinical outcomes for people living with dialysis. Haemodialysis as it is conventionally practiced only delivers the biochemical equivalent of 10% of normal kidney function. The ACTIVE trial tested whether increasing that biochemical equivalent would improve quality of life. RESOLVE will examine whether addressing the impaired salt and water clearance of end stage kidney disease will improve cardiovascular outcomes.

本系列讲座由以下机构联合举办 (The Lecture Series is co-hosted by the following organizations)



THE UNIVERSITY OF
SYDNEY

更多信息请登陆我们的网站: www.georgeinstitute.org.cn 或联系我们 电话: 861082800577x117 邮箱: CD-Center@george.org.cn

For more information, please visit www.georgeinstitute.org.cn, or contact us, Phone: 861082800577x117, Email: CD-Center@george.org.cn